- Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
-
Lee JY, Kang ES
- KMID: 2454065
- Diabetes Metab J.
- 2019 Jun;43(3):379-380.
- doi: 10.4093/dmj.2018.0106
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
-
Kim KS
- KMID: 2454064
- Diabetes Metab J.
- 2019 Jun;43(3):377-378.
- doi: 10.4093/dmj.2018.0091
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- SGLT2 Inhibitors and Ketoacidosis: Pathophysiology and Management
-
Ku YH
- KMID: 2392329
- Korean J Med.
- 2017 Oct;92(5):443-449.
- doi: 10.3904/kjm.2017.92.5.443
Sodium-glucose cotransporter 2 inhibitors are antidiabetic drugs that increase urinary glucose excretion by inhibiting proximal tubular reabsorption of glucose in the kidney. Some sodium-glucose cotransporter 2 inhibitors have been shown... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease
-
Yang H, Park CY
- KMID: 2415852
- J Korean Diabetes.
- 2018 Jun;19(2):88-96.
- doi: 10.4093/jkd.2018.19.2.88
Nonalcoholic fatty liver disease (NAFLD) is more prevalent in diabetic patients than in non-diabetic subjects, because the two diseases share a common pathophysiological mechanism. Associated abnormalities can be observed from... -
- CITED
-
- Close
- SHARE
-
- Close
- A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
-
Hwang YC, Kim JH, Lee BW, Lee WJ
- KMID: 2466510
- Diabetes Metab J.
- 2019 Dec;43(6):898-905.
- doi: 10.4093/dmj.2018.0257
We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
-
Lee KA, Jin HY, Lee NY, Kim YJ, Park TS
- KMID: 2418722
- Diabetes Metab J.
- 2018 Aug;42(4):338-342.
- doi: 10.4093/dmj.2017.0095
The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic... -
- CITED
-
- Close
- SHARE
-
- Close
- Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
-
Park JH
- KMID: 2415849
- J Korean Diabetes.
- 2018 Jun;19(2):71-75.
- doi: 10.4093/jkd.2018.19.2.71
The management of type 2 diabetes mellitus should comprise healthy lifestyle modifications along with tailored pharmacologic treatment. Traditionally, the American Diabetes Association (ADA)'s Diabetes Management Guidelines have not prioritized specific... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice
-
Hong AR, Koo BK, Kim SW, Yi KH, Moon MK
- KMID: 2460953
- Diabetes Metab J.
- 2019 Oct;43(5):590-606.
- doi: 10.4093/dmj.2018.0134
BACKGROUND: This study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical... -
- CITED
-
- Close
- SHARE
-
- Close
